Aclaris Initiates Phase 2b ALPHA Trial of Modzatinib in Moderate-to-Severe Lichen Planus
What happened
On November 16, 2026, Aclaris announced the initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial evaluating modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus, with top line results from the oral erosive...
Source
Extracted by Autobound
From the Signal API record- Signal
- SEC 8-K
What this signalsFilings often name leadership changes, deals and spending plans.
- Filed
- Nov 16, 2026
More SEC 8-K signals at other companies
- SEC 8-KAirjoule Technologies CorporationTimothy N. White Appointed to Board of Directors Succeeding Ajay Agrawal Effective November 12, 2026SEC 8-K
- SEC 8-KAMC Robotics CorporationRecorded $0.25 million non-recurring inventory impairment associated with Vietnam supply chain relocationSEC 8-K
- SEC 8-KANI Pharmaceuticals, Inc.ANI Pharmaceuticals announces public offer to acquire Egetis TherapeuticsSEC 8-K
The full record
From the Signal API recordDetails
- CIK
- 1557746
- Accession number
- 0001104659-26-127478
- Timeframe
- Next year
- Filing year
- 2026
- Why it matters
- Clinical and commercial build-out
- Signal category
- Strategic
Topics and mentions
Regions named
- U.S.
Extraction
- Confidence
- High
- Relevance
- 85%
- Sentiment
- Positive
- Detected
- Nov 17, 2026
- signal_type
sec-8k- signal_subtype
clinicalMilestone
Use this data
Get every SEC 8-K signal for Aclaris Therapeutics, Inc. and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Aclaris Therapeutics, Inc. this week?”
Send it to your own tools
The Signal API returns SEC 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/e2de7f75-7635-4555-a546-514930392d91 returns this record as JSON. POST /v1/companies/enrich returns every signal for aclaristx.com.
{
"signal_id": "e2de7f75-7635-4555-a546-514930392d91",
"signal_type": "sec-8k",
"signal_subtype": "clinicalMilestone",
"detected_at": "2026-11-17T07:03:12.712+00:00",
"company": {
"name": "Aclaris Therapeutics, Inc.",
"domain": "aclaristx.com"
},
"data": {
"detail": "On November 16, 2026, Aclaris announced the initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial evaluating modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus, with top line results from the oral erosive lichen planus cohort expected in the second half of 2027. For sellers: Clinical research organizations, trial recruitment vendors, and specialty CROs may see demand for ongoing trial execution and future phase preparation.",
"metrics": {
"timeframe": "next_year"
},
"summary": "Aclaris Initiates Phase 2b ALPHA Trial of Modzatinib in Moderate-to-Severe Lichen Planus",
"relevance": 0.85,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1557746/000110465926127478/acrs-20261116x8k.htm",
"filing_date": "2026-11-16",
"filing_year": 2026,
"sales_relevance": "Clinical and commercial build-out",
"signal_category": "strategic",
"regions_mentioned": [
"U.S."
]
}
}
curl https://signals.autobound.ai/v1/signals/e2de7f75-7635-4555-a546-514930392d91 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"aclaristx.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.